1. Home
  2. |Insights
  3. |PODCAST: Announcing Crowell & Moring’s Regulatory Forecast 2017 and Trump: The First Year Series — C&M's Trump: The First Year Series

PODCAST: Announcing Crowell & Moring’s Regulatory Forecast 2017 and Trump: The First Year Series — C&M's Trump: The First Year Series

Client Alert | 1 min read | 05.11.17

On May 9, Crowell & Moring launched its third annual Regulatory Forecast. The 2017 edition, subtitled “What Trump Means for Business,” provides in-depth analysis on how the new administration, Congress, and the federal courts are changing the regulatory landscape and what it means for business in the months ahead. With this publication, we are also announcing the launch of our new Trump: The First Year series about the regulatory changes emerging from the White House under the new administration. In this first episode of the series, Regulatory Forecast co-editors Dan Wolff and Richard Lehfeldt sit down to discuss the Forecast and what to expect from the series.

In this 12 minute podcast, Richard and Dan discuss what you will find in our Regulatory Forecast 2017 and what lessons businesses should take from the publication. The forecast is available at crowell.com/regulatoryforecast.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....